Navigation Links
Sanofi Enters Into Research Collaboration With Biopharmaceutical Company Audion Therapeutics to Develop Potential Treatments for Hearing Loss
Date:6/16/2011

PARIS, June 16, 2011 /PRNewswire/ -- Sanofi (EURONEXT: SAN and NYSE: SNY) announced today that it has entered into a two-year research collaboration with the biopharmaceutical company Audion Therapeutics (Audion) to develop potential treatments for hearing loss through the optimization of small molecules by using a regenerative medicine approach.

(Logo: http://photos.prnewswire.com/prnh/20110616/NY20158LOGO)

This collaborative research will utilize technology developed at the Massachusetts Eye and Ear Infirmary in the Eaton-Peabody Laboratory, one of the world's largest basic research facilities dedicated to the study of hearing and deafness, by investigator and Audion co-founder Dr. Albert Edge, who has strong expertise in stem cells and inner ear biology. Audion licensed Dr. Edge's technology from Mass Eye and Ear. Under the terms of the agreement, Sanofi has an option to license technology rights from Audion related to research conducted under the collaboration.

"We are very excited about this collaboration with Sanofi that validates our thinking around developing small molecule regenerative drugs for the treatment of hearing loss," said RolfJan Rutten and Helmuth van Es, founders of Audion Therapeutics. "Sanofi's interest in the hearing loss field plus its vast experience and infrastructure in small-molecule drug discovery make them the perfect partner to move this program forward as diligently as possible."

"Our new relationship with Audion demonstrates our commitment to work with partners on conditions with unmet and growing medical needs, such as hearing loss," said Elias Zerhouni, M.D., President, Global Research & Development, Sanofi.  "This collaboration is a multi-disciplinary approach with our internal Aging Therapeutic Strategic Unit and our Early-to-Candidate Unit working together to
'/>"/>

SOURCE Sanofi
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Sanofi Pasteur Donates Tdap Vaccine to Aid Storm Victims
2. sanofi-aventis: Strong Performance of Growth Platforms in Q1 2011
3. Sanofi Pasteur Announces FDA Approval of Menactra Meningococcal Conjugate Vaccine Indication for Infants
4. Sanofi-aventis Enters into Collaboration Agreement with Stanford University Bio-X to Focus on Early-Stage Scientific Research
5. Sanofi-Aventis Completes Acquisition of Genzyme Corporation
6. Sanofi-aventis Successfully Completes Exchange Offer for Genzyme Corporation
7. Navinta LLC is Pleased to Announce US FDA Approval of Sodium Ferric Gluconate Injection in Sucrose [a generic equivalent of Ferrlecit® Injection by Sanofi Aventis] Based on Its Proprietary Technology
8. Sanofi-aventis Announces Registration Statement for CVR Related to Genzyme Acquisition Declared Effective
9. Sanofi-aventis Enters Into Research Collaboration With Columbia University to Develop New Diabetes Treatments
10. Sanofi-aventis and Regeneron Report Top-line Results from Phase III Study with aflibercept (VEGF Trap) in Second-Line Non-Small Cell Lung Cancer
11. Sanofi-Aventis Announces Approval and Closing of BMP Sunstone Acquisition Creating a Strong Consumer Health Care Platform in China
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2013)... , May 20, 2013 Sequent Medical, ... for the SL ("Single Layer") family of WEB ® ... release of these new models in select neurovascular centers ... and superior navigability that will enable physicians to treat ... The SL configurations are made possible by ...
(Date:5/20/2013)... ATLANTA , May 20, 2013  Atlantic ... developed and is commercializing a unique technology to ... founder and President, Anthony Soscia ... the Atlanta Business Chronicle ,s Health-Care Heroes ... Atlanta Business Chronicle to honor individuals and ...
(Date:5/20/2013)... 20, 2013 Enrollment of patients with Type ... dose-finding clinical trial of product candidate NewMet ™, ... for Type 2 diabetes. Elcelyx expects to complete enrollment ... June. Results of the trial,s primary endpoint of change ... and the read-out for long-term glucose lowering and weight ...
Breaking Medicine Technology:Sequent Medical, Inc. Launches New SL Family of WEB Aneurysm Embolization Devices 2Atlantic Pharmaceuticals President Named Health Care Hero Finalist in Atlanta Business Chronicle for Drug Abuse Deterrent Technology 2Elcelyx Therapeutics Enrolling Phase 2b Trial of NewMet for Type 2 Diabetes 2Elcelyx Therapeutics Enrolling Phase 2b Trial of NewMet for Type 2 Diabetes 3Elcelyx Therapeutics Enrolling Phase 2b Trial of NewMet for Type 2 Diabetes 4
... Karyopharm Therapeutics Inc., a leader in the new field of ... nuclear transport machinery plays an integral role in the regulation of ... disease. Karyopharm is focused on the discovery and development of novel ... n uclear e xport (SINE) ...
... CLEVELAND, Nov. 3, 2010 From pill-sized cameras to radioactive ... Clinic,s Top 10 Medical Innovations for 2011 showcases new techniques, ... The list of breakthrough devices and therapies was selected ... unveiled during Cleveland Clinic,s 2010 Medical Innovation Summit. ...
Cached Medicine Technology:Karyopharm Therapeutics Inc. Closes $20 Million Series A Financing to Advance Pipeline of Novel Nuclear Transport Modulators for Cancer, Inflammation and Other Disorders 2Karyopharm Therapeutics Inc. Closes $20 Million Series A Financing to Advance Pipeline of Novel Nuclear Transport Modulators for Cancer, Inflammation and Other Disorders 3Cleveland Clinic Unveils Top 10 Medical Innovations for 2011 2Cleveland Clinic Unveils Top 10 Medical Innovations for 2011 3Cleveland Clinic Unveils Top 10 Medical Innovations for 2011 4
(Date:5/20/2013)... May 20, 2013 The judge overseeing ... lawsuits has called specifically for female lawyers to be ... The Rottenstein Law Group LLP acknowledges the judge’s request, ... lawsuits by providing information on Mirena side effects ... Seibel called for the addition of some female lawyers ...
(Date:5/20/2013)... N.C. May 20, 2013 Nearly 20 percent ... the U.S. are refused for transplant due to factors ... kidney,s filtering units to the organ going too long ... being discarded, these organs could be "recycled" to help ... at Wake Forest Baptist Medical Center and colleagues, reporting ...
(Date:5/20/2013)... 20 May 2013 While Huntington,s disease (HD) ... that new disease-modifying therapies in development may slow ... HD research depends upon the identification of reliable ... therapies, and these biomarkers may eventually be used ... be especially helpful to monitor changes during the ...
(Date:5/20/2013)... May 20, 2013 Dorland Health, ... of the fourth annual Case In Point Platinum ... committed to ensuring the system is patient- and ... the innovative and creative work across the healthcare ... ensuring safe transitions of care through effective care ...
(Date:5/20/2013)... Stemedica Cell Technologies , ... manufacturing, research and development, announced today that Robert ... of Interventional Cardiology Research at the University of ... Medical Advisory Board for Stemedica’s Cardiology Division. ... divides his time between the cardiac catheterization laboratories ...
Breaking Medicine News(10 mins):Health News:Mirena IUD Lawsuit Update: Judge Calls for More Input from Female Lawyers, Notes Rottenstein Law Group LLP 2Health News:Study suggests new source of kidneys for transplant 2Health News:Leading researchers report on the elusive search for biomarkers in Huntington's disease 2Health News:Leading researchers report on the elusive search for biomarkers in Huntington's disease 3Health News:Dorland Health Announces the 2013 Case In Point Platinum Awards Winners 2Health News:Noted Cardiologist Robert Wilensky to Join Stemedica Cardiology Division Scientific & Medical Advisory Board 2Health News:Noted Cardiologist Robert Wilensky to Join Stemedica Cardiology Division Scientific & Medical Advisory Board 3
... York, NY July 12, 2009) Researchers at ... compound called NIC5-15, might be a safe and effective ... to moderate Alzheimer,s disease. The two investigators, Giulio Maria ... Phase IIA preliminary clinical findings at the Alzheimer,s Association ...
... ... for Sports Medicine ,s (AOSSM) Annual Meeting in Keystone, Colorado, (July 9-12) details the benefits ... age of 14. , ... CO (Vocus) July 12, 2009 -- More and more children are participating and getting hurt ...
... strategies should help in staying calm and moving on ... for the stress level, as many in the midst of ... not surprisingly, nearly half of the 1,791 adults polled for ... that their stress had increased in the past year. As ...
... Ill., July 11, 2009 The Natural Orifice ... joint effort of the American Society for Gastrointestinal ... and Endoscopic Surgeons (SAGES), today announced Olympus, continuing ... invasive transdisciplinary therapy known as Natural Orifice Translumenal ...
... , ROCHESTER, Minn., July 11 A new Mayo ... neurodegenerative disorders in the future. The study will be ... Disease on July 11 in Vienna. , ... framework for MRI-based differential diagnosis of three common neurodegenerative ...
... ... other North American physicians as a 2009 American Orthopaedic Society for Sports Medicine ... ... Cleveland Clinic Foundation, Director of Operating Room Management, will join three other North American ...
Cached Medicine News:Health News:Mount Sinai researchers find new Alzheimer's disease treatment promising 2Health News:Risks of Delaying ACL Reconstruction in Young Athletes May Be Too High, Study Shows 2Health News:Risks of Delaying ACL Reconstruction in Young Athletes May Be Too High, Study Shows 3Health News:How to De-Stress a Recession-Riddled Life 2Health News:How to De-Stress a Recession-Riddled Life 3Health News:NOSCAR increases NOTES research with Olympus Medical Systems Corporation grant 2Health News:Mayo Clinic Study Using Structural MRI May Help Accurately Diagnose Dementia Patients 2Health News:Renowned, Cleveland Clinic Foundation, Orthopaedic Sports Medicine Surgeon, John Bergfeld, MD, Inducted into Sports Medicine Hall of Fame 2
For the quantitative determination of aspartate aminotransferase in serum. Optimized IFCC procedure without P-5'-P. 500 IU/L at 37C linearity....
The Definitive automated slide stainer is an industry standard. The Definitive allows automated slide staining in a compact, self-contained and easy-to use package....
... is an "assembly-line worker" for routine staining ... laboratories. Programmable continuous slide stainer for routine ... slides in short time. Its large number ... continuous working principle provides a high throughput. ...
HMS 760 Robot Stainer. Version includes display....
Medicine Products: